Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis - PubMed (original) (raw)
Randomized Controlled Trial
. 2010 Jan 14;362(2):118-28.
doi: 10.1056/NEJMoa0810652.
Bruce E Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, Bei Zhou, Shu Li, Lisa T Dooley, Neil H Goldstein, Alan Menter; ACCEPT Study Group
Affiliations
- PMID: 20071701
- DOI: 10.1056/NEJMoa0810652
Free article
Randomized Controlled Trial
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
Christopher E M Griffiths et al. N Engl J Med. 2010.
Free article
Abstract
Background: Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known. We compared two biologic agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor alpha), for the treatment of psoriasis.
Methods: We randomly assigned 903 patients with moderate-to-severe psoriasis to receive subcutaneous injections of either 45 or 90 mg of ustekinumab (at weeks 0 and 4) or high-dose etanercept (50 mg twice weekly for 12 weeks). The primary end point was the proportion of patients with at least 75% improvement in the psoriasis area-and-severity index (PASI) at week 12; a secondary end point was the proportion with cleared or minimal disease on the basis of the physician's global assessment. Assessors were unaware of the treatment assignments. The efficacy and safety of a crossover from etanercept to ustekinumab were evaluated after week 12.
Results: There was at least 75% improvement in the PASI at week 12 in 67.5% of patients who received 45 mg of ustekinumab and 73.8% of patients who received 90 mg, as compared with 56.8% of those who received etanercept (P=0.01 and P<0.001, respectively). Similarly, 65.1% of patients who received 45 mg of ustekinumab and 70.6% of patients who received 90 mg of ustekinumab had cleared or minimal disease according to the physician's global assessment, as compared with 49.0% of those who received etanercept (P<0.001 for both comparisons). Among patients who did not have a response to etanercept, 48.9% had at least 75% improvement in the PASI within 12 weeks after crossover to ustekinumab. One or more adverse events occurred through week 12 in 66.0% of patients who received 45 mg of ustekinumab and 69.2% of patients who received 90 mg of ustekinumab and in 70.0% who received etanercept; 1.9%, 1.2%, and 1.2%, respectively, had serious adverse events. Safety patterns were similar before and after crossover from etanercept to ustekinumab.
Conclusions: The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis. (ClinicalTrials.gov number, NCT00454584.)
2010 Massachusetts Medical Society
Similar articles
- Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
[No authors listed] [No authors listed] Prescrire Int. 2009 Oct;18(103):202-4. Prescrire Int. 2009. PMID: 19882785 - Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept Pediatric Psoriasis Study Group. Paller AS, et al. N Engl J Med. 2008 Jan 17;358(3):241-51. doi: 10.1056/NEJMoa066886. N Engl J Med. 2008. PMID: 18199863 Clinical Trial. - Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
Uhlenhake EE, Feldman SR. Uhlenhake EE, et al. Expert Opin Biol Ther. 2010 Jul;10(7):1105-12. doi: 10.1517/14712598.2010.487061. Expert Opin Biol Ther. 2010. PMID: 20446825 Review. - Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R. Woolacott N, et al. Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460. Health Technol Assess. 2006. PMID: 17083854 Review.
Cited by
- Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis.
Engesser J, Khatri R, Schaub DP, Zhao Y, Paust HJ, Sultana Z, Asada N, Riedel JH, Sivayoganathan V, Peters A, Kaffke A, Jauch-Speer SL, Goldbeck-Strieder T, Puelles VG, Wenzel UO, Steinmetz OM, Hoxha E, Turner JE, Mittrücker HW, Wiech T, Huber TB, Bonn S, Krebs CF, Panzer U. Engesser J, et al. Nat Commun. 2024 Sep 19;15(1):8220. doi: 10.1038/s41467-024-52525-w. Nat Commun. 2024. PMID: 39300109 Free PMC article. - The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and Psoriatic Arthritis.
Shi ZR, Mabuchi T, Riutta SJ, Wu X, Peterson FC, Volkman BF, Hwang ST. Shi ZR, et al. J Psoriasis Psoriatic Arthritis. 2023 Jul;8(3):107-117. doi: 10.1177/24755303231159106. Epub 2023 Mar 12. J Psoriasis Psoriatic Arthritis. 2023. PMID: 39296310 Free PMC article. Review. - [Head-to-head studies on psoriasis and psoriatic arthritis].
Albach FN, Köhm M, Simon D. Albach FN, et al. Z Rheumatol. 2024 Oct;83(8):634-640. doi: 10.1007/s00393-024-01556-1. Epub 2024 Aug 14. Z Rheumatol. 2024. PMID: 39143256 Review. German. - Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis.
Shellard EM, Rane SS, Eyre S, Warren RB. Shellard EM, et al. Biomolecules. 2024 May 3;14(5):548. doi: 10.3390/biom14050548. Biomolecules. 2024. PMID: 38785955 Free PMC article. Review. - Tobacco smoking negatively influences the achievement of greater than three-quarters reduction in psoriasis area and severity index after eight weeks of treatment among patients with psoriasis: Findings from a prospective study.
Qiang Y, Kuai L, Liu S, Xu Q, Shenfan L, Zhang R, Gao Z, Gao X, Li B, Wang R. Qiang Y, et al. Tob Induc Dis. 2024 Apr 11;22. doi: 10.18332/tid/184143. eCollection 2024. Tob Induc Dis. 2024. PMID: 38605857 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical